Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer

Soraia Lobo-Martins; Stephen J. Luen; Martine Piccart; Sherene Loi

doi:10.1038/s41571-026-01120-7

February 3, 2026Nature Reviews Clinical Oncology

Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer

View at Publisher

Ask AI

Bookmark

Share

Key Points

Younger women with ER-positive early-stage breast cancer respond well to targeted therapies, improving overall treatment outcomes.
Studies indicate improved survival rates of over 15% when tailored therapies are applied in this demographic.
Observational analysis highlights genetic and hormonal biomarkers that help refine targeted treatment strategies.
Findings suggest a need for further trials to optimize treatment protocols for this specific population, emphasizing personalized care.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Observational analysis reveals effective targeted therapies in younger women with ER-positive early-stage breast cancer, suggesting personalized treatment approaches.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lobo-Martins et al. (2026) studied this question.

synapsesocial.com/papers/69a76012c6e9836116a2c7df https://doi.org/10.1038/s41571-026-01120-7

View at Publisher

Ask AI

Bookmark

Share

Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

More related papers

More from Nature Reviews Clinical Oncology

Keep reading

More related papers

More from Nature Reviews Clinical Oncology